Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastoma

Glioblastoma (GBM) is a highly malignant brain cancer with a poor prognosis despite standard treatments. This investigation aimed to explore the feasibility of PTPN6 to combat GBM with immunotherapy. Our study employed a comprehensive analysis of publicly available datasets and functional experiments to assess PTPN6 gene expression, prognostic value, and related immune characteristics in glioma. We evaluated the influence of PTPN6 expression on CD8+ T cell exhaustion, immune suppression, and tumor growth in human GBM samples and mouse models. Our findings demonstrated that PTPN6 overexpression played an oncogenic role in GBM and was associated with advanced tumor grades and unfavorable clinical outcomes. In human GBM samples, PTPN6 upregulation showed a strong association with immunosuppressive formation and CD8+ T cell dysfunction, whereas, in mice, it hindered CD8+ T cell infiltration. Moreover, PTPN6 facilitated cell cycle progression, inhibited apoptosis, and promoted glioma cell proliferation, tumor growth, and colony formation in mice. The outcomes of our study indicate that PTPN6 is a promising immunotherapeutic target for the treatment of GBM. Inhibition of PTPN6 could enhance CD8+ T cell infiltration and improve antitumor immune response, thus leading to better clinical outcomes for GBM patients.

[1]  Bin Bai,et al.  Pan-cancer analyses of classical protein tyrosine phosphatases and phosphatase-targeted therapy in cancer , 2022, Frontiers in Immunology.

[2]  Xiao Guo,et al.  Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures , 2022, Frontiers in Immunology.

[3]  H. Takematsu,et al.  The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells , 2021, The Journal of Immunology.

[4]  Zhen-ping Zhu,et al.  Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition , 2021, Acta pharmacologica Sinica.

[5]  F. Lieberman,et al.  TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma , 2021, Frontiers in Immunology.

[6]  G. Hu,et al.  BFAR coordinates TGFβ signaling to modulate Th9-mediated cancer immunotherapy , 2021, The Journal of experimental medicine.

[7]  C. Langer,et al.  Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. , 2021, JAMA oncology.

[8]  J. Larkin,et al.  Predictive biomarkers for response to immune checkpoint inhibition. , 2021, Seminars in cancer biology.

[9]  Xinying Zhang,et al.  The role of Src homology region 2 domain-containing phosphatase-1 hypermethylation in the classification of patients with myelodysplastic syndromes and its association with signal transducer and activator of transcription 3 phosphorylation in skm-1 cells , 2021, The Journal of international medical research.

[10]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[11]  Wei-Qing Ma,et al.  PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway , 2020, Cell biochemistry and function.

[12]  S. Iborra,et al.  SHP-1 Regulates Antigen Cross-Presentation and Is Exploited by Leishmania to Evade Immunity. , 2020, Cell reports.

[13]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. , 2020, Neuro-oncology.

[14]  M. Goldsmith,et al.  Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity , 2020, Frontiers in Immunology.

[15]  Jing Wang,et al.  Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers , 2020, Nature Communications.

[16]  Haitao Niu,et al.  The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA , 2020, Disease markers.

[17]  Z. Wang,et al.  Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients , 2020, bioRxiv.

[18]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[19]  Shaowei Zhang,et al.  Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma. , 2019, Molecular medicine reports.

[20]  G. Mills,et al.  Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy , 2019, Nature Metabolism.

[21]  Wei Liu,et al.  CancerSEA: a cancer single-cell state atlas , 2018, Nucleic Acids Res..

[22]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[23]  James A. Eddy,et al.  The Immune Landscape of Cancer. , 2018, Immunity.

[24]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[25]  R. Grossman,et al.  Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies , 2017, Genome research.

[26]  Altaf Ahmad,et al.  Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways. , 2016, Future oncology.

[27]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[28]  O. Gallego,et al.  Nonsurgical treatment of recurrent glioblastoma. , 2015, Current oncology.

[29]  F. Krötz,et al.  The Tyrosine Phosphatase SHP-1 Regulates Hypoxia Inducible Factor-1α (HIF-1α) Protein Levels in Endothelial Cells under Hypoxia , 2015, PloS one.

[30]  A. Zakrzewska,et al.  Deficiency in Hematopoietic Phosphatase Ptpn6/Shp1 Hyperactivates the Innate Immune System and Impairs Control of Bacterial Infections in Zebrafish Embryos , 2013, The Journal of Immunology.

[31]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[32]  S. Leenstra,et al.  Recent advances in the molecular understanding of glioblastoma , 2012, Journal of Neuro-Oncology.

[33]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[34]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[35]  Wanling Yang,et al.  Linked region detection using high-density SNP genotype data via the minimum recombinant model of pedigree haplotype inference , 2009, BMC Bioinformatics.

[36]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[37]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[38]  Robert L Bowman,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.